Read about clinical progress demonstrating safety and CNS exposure for a neurotrophic small molecule targeting dementia and mood disorders.
Key Takeaways
- ACD856 was well tolerated with no substance-related safety findings
- Repeated higher dosing produced expected increases in blood and cerebrospinal fluid concentrations
- Results support Phase II studies expected in 2026 following a 2025 European Innovation Council grant